Mirna for the Treatment of Metastatic Breast Cancer
Metastasis is the primary cause for mortality in breast cancer.
We showed that breast cancer metastasis can be prevented by miR-96 or miR-182 treatment. We found that miR-96/miR-182 downregulates Palladin protein levels, thereby reducing breast cancer cell migration and invasion.
A hydrogel-embedded, gold-nanoparticle-based delivery vehicle provides efficient local, selective, and sustained release of miR-96/miR-182, markedly suppressing metastasis in a breast cancer mouse model. Combined delivery of the miRNAs with a chemotherapy drug, cisplatin, enables significant primary tumor shrinkage and metastasis prevention.
Stage of Development
In Vivo proof of concept. Additional delivery systems are investigated.
Granted US and Europe patents.
“Local microRNA delivery targets Palladin and prevents metastatic breast cancer”. Nature communications 7 (1), 1-14, 2016